Abstract
Immune checkpoint blockade plus chemotherapy is emerging as a standard treatment for some patients with triple-negative breast cancer (TNBC). In this issue of Cancer Cell, Zhang et al. employ extensive single-cell immune compartment analyses of pre- and post-therapy TNBC, and they reveal potential mechanisms of T cell activation and patterns of immune evolution that may inform future biomarkers of response and clinical benefit.
Original language | English |
---|---|
Pages (from-to) | 1562-1564 |
Number of pages | 3 |
Journal | Cancer Cell |
Volume | 39 |
Issue number | 12 |
Early online date | 8 Nov 2021 |
DOIs | |
Publication status | Published - 13 Dec 2021 |
Bibliographical note
Publisher Copyright:Copyright © 2021 Elsevier Inc. All rights reserved.